Laboratorio Barnafi-Krause is Live on SOPHiA DDM™
BOSTON and ROLLE, Switzerland, April 2, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Laboratorio Barnafi-Krause is live on the SOPHiA DDM™ Platform. Laboratorio Barnafi-Krause, located in Chile, has implemented SOPHiA GENETICS' technology to help elevate its testing and analysis of blood cancers and diseases, including Leukemia.
- BOSTON and ROLLE, Switzerland, April 2, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Laboratorio Barnafi-Krause is live on the SOPHiA DDM™ Platform.
- Laboratorio Barnafi-Krause, located in Chile, has implemented SOPHiA GENETICS' technology to help elevate its testing and analysis of blood cancers and diseases, including Leukemia.
- With the SOPHiA DDM™ Platform, Laboratorio Barnafi-Krause will offer tailored NGS-based workflows that enable accurate and sensitive characterization of the complex mutational landscape associated with blood disorders.
- For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .